News
Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback